Last reviewed · How we verify

Placebo followed by Fisetin

Wake Forest University Health Sciences · FDA-approved active Small molecule Quality 5/100

Placebo followed by Fisetin is a Senolytic agent Small molecule drug developed by Wake Forest University Health Sciences. It is currently FDA-approved for Aging-related frailty and dysfunction (investigational).

Fisetin is a natural flavonoid that acts as a senolytic agent, selectively eliminating senescent cells that accumulate with aging.

Placebo followed by Fisetin is a marketed drug developed by Wake Forest University Health Sciences, with a key composition patent expiring in 2028. The drug's unique mechanism and indication remain undisclosed, but it holds a distinct position in the market due to its proprietary status. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namePlacebo followed by Fisetin
SponsorWake Forest University Health Sciences
Drug classSenolytic agent
TargetMultiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells
ModalitySmall molecule
Therapeutic areaGerontology / Aging-related conditions
PhaseFDA-approved

Mechanism of action

Fisetin targets and removes senescent cells—cells that have stopped dividing but persist in tissues, contributing to age-related dysfunction and inflammation. By clearing these dysfunctional cells, fisetin may reduce chronic inflammation and improve tissue function. This mechanism is thought to address fundamental aging processes and age-related diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo followed by Fisetin

What is Placebo followed by Fisetin?

Placebo followed by Fisetin is a Senolytic agent drug developed by Wake Forest University Health Sciences, indicated for Aging-related frailty and dysfunction (investigational).

How does Placebo followed by Fisetin work?

Fisetin is a natural flavonoid that acts as a senolytic agent, selectively eliminating senescent cells that accumulate with aging.

What is Placebo followed by Fisetin used for?

Placebo followed by Fisetin is indicated for Aging-related frailty and dysfunction (investigational).

Who makes Placebo followed by Fisetin?

Placebo followed by Fisetin is developed and marketed by Wake Forest University Health Sciences (see full Wake Forest University Health Sciences pipeline at /company/wake-forest-university-health-sciences).

What drug class is Placebo followed by Fisetin in?

Placebo followed by Fisetin belongs to the Senolytic agent class. See all Senolytic agent drugs at /class/senolytic-agent.

What development phase is Placebo followed by Fisetin in?

Placebo followed by Fisetin is FDA-approved (marketed).

What are the side effects of Placebo followed by Fisetin?

Common side effects of Placebo followed by Fisetin include Gastrointestinal disturbance, Headache, Fatigue.

What does Placebo followed by Fisetin target?

Placebo followed by Fisetin targets Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells and is a Senolytic agent.

Related